摘要
目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者血清中乙酰肝素酶(heparanase,HPA)和血管内皮生长因子(vascular endothelial growth factor,VEGF)水平检测的意义。方法:56例NSCLC患者纳入研究,以21例健康志愿者为正常对照组,比较分析两组受试者血清中乙酰肝素酶、VEGF水平的差异,并与临床病理特征进行比较分析。结果:在NSCLC患者血清乙酰肝素酶和VEGF水平显著高于正常对照组。在NSCLC患者中,血清乙酰肝素酶和VEGF水平在低分化、临床Ⅲ+Ⅳ期和淋巴结转移阳性患者中较高,与患者性别、年龄、病理类型无关。血清乙酰肝素酶与VEGF水平显著正相关。结论:NSCLC患者血清乙酰肝素酶及VEGF水平显著高于正常水平,与NSCLC的生长、浸润和转移有关,可作为判断NSCLC预后及指导治疗的指标。
Objective：To investigate the clinical significance of detection of serum heparanase and vascular endothelial growth factor in patients with Non-small cell lung cancer. Methods：56 cases of NSCLC patients were included in the study with 21 healthy volunteers as the normal control group. A comparative analysis of the serum heparanase and VEGF levels in the two groups was performed. The relationship of the serum heparanase and VEGF levels with the clinicopathological characteristics of NSCLC was also analyzed. Results：The serum heparanase and VEGF levels was significantly higher In NSCLC patients than in the normal control group. In NSCLC patients,serum heparanase and VEGF levels were higher in patients with poorly differentiated,Ⅲ ＋ Ⅳ clinical stage and lymph node-positive NSCLC. Sex,age,pathological type of the NSCLC patients did not have impact on the serum heparanase and VEGF levels. A significant positive correlation of serum heparanase and VEGF levels was observed in NSCLC patients but not in the normal control group. Conclusion：The high serum levels of heparanase and VEGF in patints with NSCLC are correlated with the growth,invasion and metastasis of NSCLC. NSCLC could be used as a predicting biomarker in the treatment and prognosis of patients with NSCLC.
出处
《现代生物医学进展》
CAS
2009年第21期4099-4101,共3页
Progress in Modern Biomedicine
